首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

1634226

全球光動力治療市場 - 2024 - 2032

Global Photodynamic Therapy Market - 2024 - 2032

出版日期: 2025年01月13日 | 出版商:

DataM Intelligence | 英文 179 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024年，全球光動力治療市場規模達53億美元，預計2032年將達到104億美元，2024-2032年預測期間複合年成長率為8.8%。

光動力療法(PDT) 是一種尖端的非侵入性治療方法，使用稱為光敏劑的光敏物質，當光敏劑被光激活時，有助於治療各種醫療狀況，包括癌症、皮膚問題和感染。該療法涉及施用一種被異常或患病細胞吸收的光敏劑。當這些細胞暴露於特定的光波長時，光敏劑被激活，產生活性氧，選擇性地損傷目標細胞。

PDT 因其能夠提供精確、有針對性的治療而廣受歡迎，與手術和化療等傳統療法相比，副作用更少。它對於治療早期或表面癌症特別有效，包括皮膚、肺部、食道和頭頸等部位的癌症。除了癌症之外，PDT 在治療痤瘡、老年黃斑部病變 (AMD) 和某些病毒感染等疾病方面也取得了成功。人們對 PDT 日益濃厚的興趣凸顯了其作為現代醫學中多功能、微創治療選擇的潛力。

市場動態：

驅動程式和限制

癌症盛行率上升

皮膚癌，特別是基底細胞癌（BCC）和鱗狀細胞癌（SCC）等非黑色素瘤類型的盛行率不斷上升，預計將顯著推動光動力療法（PDT）市場的發展。皮膚癌病例的增加可歸因於長時間暴露在陽光下、曬黑習慣和人口老化等因素。因此，對 PDT 等有效、非侵入性治療方法的需求不斷增加。全球皮膚癌的數量不斷增加。例如，根據世界癌症研究基金會的數據，2022 年有超過 331,722 例新發皮膚癌。

PDT 在治療皮膚癌方面具有幾個關鍵優勢。它對於淺表或早期癌症特別有效，這些癌症通常在深入皮膚之前就被發現。 PDT 無需侵入性手術即可精確靶向癌細胞的能力使其成為極具吸引力的選擇，特別是對於腫瘤位於敏感或可見區域（例如面部和頭皮）的患者。此外，與傳統外科手術相比，PDT 具有較低的疤痕和併發症風險，從而增強了其在皮膚癌治療中的吸引力。

隨著皮膚癌發病率持續上升，醫療保健提供者和患者擴大考慮 PDT，因為它能夠提供局部、有針對性的治療，且副作用最小。據估計，一段時間內皮膚癌的發生率會增加。預計在預測期內皮膚癌的數量將會增加。例如，GLOBOCAN也預測，2040年印度癌症病例將增加至208萬，較2020年增加57.5%。

此外，光敏劑和光傳輸系統的不斷進步預計將進一步提高 PDT 的有效性，擴大其在皮膚癌治療中的應用。隨著早期檢測和治療越來越受到重視，PDT 可能在解決全球皮膚癌病例激增的問題上發揮至關重要的作用。

成本高且供應有限

光動力療法（PDT）的高成本和有限的可用性預計將對市場的成長構成重大挑戰。 PDT 涉及專用設備和光敏劑，購買和維護成本高昂，這使其成為許多醫療保健提供者和患者的昂貴治療選擇。這種高昂的成本可能會限制其可近性，特別是在醫療基礎設施低度開發的地區或財政資源有限的低收入國家。此外，由於並非所有醫療機構都具備必要的專業知識或設備，因此需要訓練有素的專業人員來有效地實施治療，這進一步限制了其可用性。

BIOFRONTERA AG
Sun Pharmaceutical Industries Ltd.
Lumibird Medical
Bausch + Lomb.
illumacell
Pinnacle Biologics, Inc.
Zimed Healthcare Inc
MEDlight GmbH
Luzitin, SA
Similar data will be provided for each market player.
再生元製藥公司
- 管道產品說明
- 產品關鍵績效指標 (KPI)
- 主要活動
- 市場進入時間表
- 產品滲透率
- 銷售估算與預測
摩德納公司
伊馬蒂斯公司
BioNTech SE。
菲洛根公司
將為每個市場參與者提供類似的資料。

第 12 章：附錄

簡介目錄

Product Code: PH1036

The global photodynamic therapy market reached US$ 5.3 billion in 2024 and is expected to reach US$ 10.4 billion by 2032, growing at a CAGR of 8.8% during the forecast period 2024-2032.

Photodynamic Therapy (PDT) is a cutting-edge, non-invasive treatment that uses light-sensitive substances called photosensitizers, which, when activated by light, help to treat a variety of medical conditions, including cancer, skin issues, and infections. The therapy involves administering a photosensitizer that is absorbed by abnormal or diseased cells. When these cells are exposed to a specific light wavelength, the photosensitizer is activated, producing reactive oxygen species that selectively damage the targeted cells.

PDT has gained considerable popularity due to its ability to provide precise, targeted treatment with fewer side effects compared to traditional therapies such as surgery and chemotherapy. It is particularly effective for treating early-stage or surface-level cancers, including those in areas like the skin, lungs, esophagus, and head and neck. Beyond cancer, PDT has shown success in managing conditions such as acne, age-related macular degeneration (AMD), and certain viral infections. This growing interest in PDT highlights its potential as a versatile and minimally invasive treatment option in modern medicine.

Market Dynamics: Drivers & Restraints

Rising prevalence of cancer

The growing prevalence of skin cancer, particularly non-melanoma types such as basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), is expected to significantly boost the Photodynamic Therapy (PDT) market. This increase in skin cancer cases can be attributed to factors like extended sun exposure, tanning practices, and the aging population. As a result, the demand for effective and non-invasive treatment methods like PDT is on the rise. There is a growing number of skin cancers around the globe. For instance, according to the World Cancer Research Fund, there were more than 331,722 new cases of skin cancer in 2022.

PDT offers several key benefits in treating skin cancer. It is especially effective for superficial or early-stage cancers, which are often detected before they progress deeper into the skin. PDT's ability to target cancerous cells precisely without requiring invasive surgery makes it a highly attractive option, particularly for patients with tumors located in sensitive or visible areas, such as the face and scalp. Furthermore, PDT is associated with a lower risk of scarring and complications when compared to traditional surgical procedures, enhancing its appeal in skin cancer treatment.

As the incidence of skin cancer continues to rise, healthcare providers and patients are increasingly considering PDT for its ability to provide localized, targeted treatment with minimal side effects. There is an estimated increase in skin cancer over a while. The number of skin cancers is expected to increase in the forecast period. For instance, additionally, GLOBOCAN predicted that cancer cases in India would increase to 2.08 million, accounting for a rise of 57.5 percent in 2040 from 2020.

Additionally, ongoing advancements in photosensitizers and light delivery systems are expected to further improve PDT's effectiveness, broadening its application in skin cancer management. As early detection and treatment become increasingly emphasized, PDT is likely to play a crucial role in addressing the global surge in skin cancer cases.

High Cost and Limited Availability

The high cost and limited availability of Photodynamic Therapy (PDT) are expected to pose significant challenges to the growth of the market. PDT involves specialized equipment and photosensitizers, which can be expensive to acquire and maintain, making it a costly treatment option for many healthcare providers and patients. This high cost can limit its accessibility, especially in regions with less advanced healthcare infrastructure or in lower-income countries where financial resources are constrained. Additionally, the need for trained professionals to administer the therapy effectively further restricts its availability, as not all healthcare facilities have the necessary expertise or equipment.

Segment Analysis

The global photodynamic therapy market is segmented based on product type, application, end-user, and region.

Type:

Laser devices segment is expected to dominate the global photodynamic therapy market share

The Laser Devices segment is poised to dominate the Photodynamic Therapy (PDT) market due to their critical role in the therapy's mechanism of action. Laser devices are essential for activating the photosensitizers used in PDT, delivering the precise wavelengths of light required to treat a variety of conditions, such as skin cancer, acne, and age-related macular degeneration. The ability of lasers to provide highly targeted, accurate, and deep tissue penetration makes them a preferred choice for PDT, as they allow clinicians to focus the treatment on specific areas without causing damage to surrounding healthy tissues.

The segment's growth is also fueled by ongoing technological advancements and product launches. Manufacturers are continuously improving laser devices to enhance their efficiency, precision, and safety. For instance, companies are introducing lasers that offer more adjustable wavelengths, better depth control, and compact designs, making them easier to use in clinical settings. These innovations are expected to further elevate the adoption of laser devices in PDT. For instance, in February 2023, Bausch + Lomb Corp. and biomedical laser firm Modulight Oyj announced that the US Food and Drug Administration has approved their ML6710i photodynamic laser for use with the eye-health company's photodynamic therapy, Visudyne.

Market players are employing strategies that focus on expanding their product portfolios and advancing their technological capabilities. Leading companies in the PDT space are investing in research and development to create next-generation laser devices that can offer more effective treatment options, including improved portability and user-friendly features. Additionally, strategic partnerships and collaborations with healthcare institutions help to increase awareness and availability of laser-based PDT treatments.

As a result of these advancements, laser devices are expected to maintain their dominance in the PDT market, particularly as the demand for non-invasive, precise, and effective treatments grows. With continued product innovation, strategic market moves, and an increasing focus on patient outcomes, the laser devices segment is set to be a key driver of the Photodynamic Therapy market's expansion.

Geographical Analysis

North America is expected to hold a significant position in the global photodynamic therapy market share

North America is expected to dominate the photodynamic therapy (PDT) market due to a combination of factors including advanced healthcare infrastructure, a high prevalence of diseases treatable with PDT (such as skin cancer and age-related macular degeneration), and a strong presence of key market players and research institutions. The region is a leader in the adoption of innovative medical technologies, making it a hub for the development and deployment of PDT treatments.

The major factor driving the region's photodynamic therapy is the rising incidence of skin cancers in the region. With the growing number of skin cancers, the estimated usage and adoption of photodynamic therapy is expected to increase. For instance, according to the American Academy of Dermatology, skin cancer is the most prevalent cancer in the United States. Current estimates suggest that one in five Americans will be diagnosed with skin cancer during their lifetime. Approximately 9,500 people in the U.S. are diagnosed with skin cancer every day. In 2024, it is projected that there will be 200,340 new cases of melanoma, with 99,700 being noninvasive (in situ) and 100,640 being invasive.

Additionally, North America's dominance is the increasing demand for non-invasive, precise, and targeted therapies. PDT offers a compelling alternative to traditional treatments like surgery and chemotherapy, particularly for conditions like superficial cancers, acne, and eye disorders. As awareness of PDT's benefits grows among both patients and healthcare providers, its adoption is expected to increase. Furthermore, North America boasts a well-established healthcare system that facilitates the widespread availability of advanced treatments such as PDT.

In addition, ongoing product launches and innovations from major market players are contributing to the growth of the PDT market in North America. Companies are introducing new PDT devices, particularly laser-based systems, that offer enhanced precision, improved light delivery mechanisms, and better photosensitizers.

Market players in North America are adopting various strategies to strengthen their positions in the PDT market. Key strategies include increasing investment in research and development to create next-generation PDT technologies, expanding product portfolios, and forging partnerships with hospitals, dermatology clinics, and research institutions. Strategic collaborations are helping to expand the reach of PDT treatments, while partnerships with regulatory bodies and clinical researchers enable quicker approvals and clinical trials, thereby speeding up the adoption of new PDT solutions. Thus, the above factors are expected to hold a significant position in the global photodynamic therapy market.

Competitive Landscape

The major global players in the photodynamic therapy market include Galderma Nordic AB, BIOFRONTERA AG, Sun Pharmaceutical Industries Ltd., Lumibird Medical, Bausch + Lomb., illumacell, Pinnacle Biologics, Inc., Zimed Healthcare Inc, MEDlight GmbH and Luzitin, S.A. among others.

Key Developments

In July 2023, ImPact Biotech announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Padeliporfin Vascular Targeted Photodynamic Therapy (VTP) for the treatment of patients with locally advanced pancreatic cancer.
In October 2024, Biofrontera Inc. (Nasdaq: BFRI) announced that the database for the treatment phase of the ALA-BCC-CT013 study has been finalized.

Why Purchase the Report?

Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
Post-market Surveillance: Uses post-market data to enhance product safety and access.
Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Photodynamic Therapy Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
Supply Chain: Distribution and Supply Chain Managers.
Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
Academic & Research: Academic Institutions.

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Application
3.3. Snippet by End-User
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising prevalence of cancer
- 4.1.2. Restraints
  - 4.1.2.1. High Cost and Limited Availability
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Patent Analysis
5.5. Regulatory Analysis
5.6. SWOT Analysis
5.7. Unmet Needs

6. By Product Type

6.1. Introduction
- 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 6.1.2. Market Attractiveness Index, By Product Type
6.2. Photosensitizer Drugs*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.2.3. Porphyrin Derivatives
- 6.2.4. Chlorines
- 6.2.5. Aminolevulinic Acid
- 6.2.6. Others
6.3. Laser Devices

7. By Application

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 7.1.2. Market Attractiveness Index, By Application
7.2. Oncology*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Dermatology
7.4. Ophthalmology
7.5. Others

8. By End-User

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 8.1.2. Market Attractiveness Index, By End-User
8.2. Hospitals*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Cosmetic & Dermatology Clinics
8.4. Cancer Treatment Centers
8.5. Others

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.2.6.1. U.S.
  - 9.2.6.2. Canada
  - 9.2.6.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.6.1. Germany
  - 9.3.6.2. U.K.
  - 9.3.6.3. France
  - 9.3.6.4. Spain
  - 9.3.6.5. Italy
  - 9.3.6.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.4.6.1. Brazil
  - 9.4.6.2. Argentina
  - 9.4.6.3. Rest of South America
9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.5.6.1. China
  - 9.5.6.2. India
  - 9.5.6.3. Japan
  - 9.5.6.4. South Korea
  - 9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

Key Market Players

11.1. Galderma Nordic AB*
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio
  - 11.1.2.1. Product Description
  - 11.1.2.2. Product Key Performance Indicators (KPIs)
  - 11.1.2.3. Historic and Forecasted Product Sales
  - 11.1.2.4. Product Sales Volume
- 11.1.3. Financial Overview
  - 11.1.3.1. Company Revenue's
  - 11.1.3.2. Geographical Revenue Shares
  - 11.1.3.3. Revenue Forecasts
- 11.1.4. Key Developments
  - 11.1.4.1. Mergers & Acquisitions
  - 11.1.4.2. Key Product Development Activities
  - 11.1.4.3. Regulatory Approvals etc.
- 11.1.5. SWOT Analysis
11.2. BIOFRONTERA AG
11.3. Sun Pharmaceutical Industries Ltd.
11.4. Lumibird Medical
11.5. Bausch + Lomb.
11.6. illumacell
11.7. Pinnacle Biologics, Inc.
11.8. Zimed Healthcare Inc
11.9. MEDlight GmbH
11.10. Luzitin, S.A.
Similar data will be provided for each market player.

Emerging Market Players

11.11. Regeneron Pharmaceuticals Inc.*
- 11.11.1. Pipeline Products Description
- 11.11.2. Product Key Performance Indicators (KPIs)
- 11.11.3. Key Activities
- 11.11.4. Market Entry Timelines
- 11.11.5. Product Penetration Rate
- 11.11.6. Sales Estimation and Projections
11.12. Moderna, Inc.
11.13. Immatics N.V.
11.14. BioNTech SE.
11.15. Philogen S.p.A.
Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE